Ceren Güzelalp

Coordinated relationships with patient associations across Turkey and supported regional/global visibility. Advocated for high-priority public policy issues, supporting Sanofi’s effort to reach its business goals. Supported head of public affairs for Genzyme portfolio. Managed government affairs coordinator. • Supported establishment of Parliament Rare Diseases Commission and Autism and Rare Diseases Departments within Ministry of Health. • Identified applicable government health and investment policy programs and regulations to support development of Sanofi Group’s position and action plans regarding compliance of company operations. Prepared SOPs on responsible lobbying and interactions with patients/patient groups. • Positioned Sanofi as reliable government partner through ongoing localisation projects that differentiated position as localised, multinational company with R&D expertise and global access to export markets. Established Sanofi as a strategic, supportive partner during COVID-19. Led awareness and training projects focused on diabetes and rare diseases. • Negotiated with government officials to shape the policy environment and secure endorsements aligned with Sanofi’s business needs. • Provided policy support to new product launches, initiative to advocate against switch to biosimilar products, and regulatory and market access issues; identified effective policies, applicable regulations, and barriers to success. • Supported market research on out-of-pocket payment market for patients with rare diseases and on effects of COVID-19 on rare diseases. Created PAG RWE (real world evidence) data to illustrate epidemiology, financial, social, and medical burdens on patients. • Preparing consensus paper for publication by KOLs and Patients Advocacy Group regarding BoD and patient journey in Rare Diseases (specifically for Lysosomal Storage Disorders). • Currently collaborating with government bodies on development of national rare disease policies and plans.

Establishing and managing relationships with key stakeholders Develop well-functioning communication channels with all partners and stakeholders in order to create/raise awareness on Rare Diseases and Orphan Drugs Pro-actively monitoring Health Policy Environment and making necessary assesments on the implications on business Developing and leading lobbying activities Strategic thinking and decision making as a Management Team member Work closely with and support the international regulatory and market access teams Develop P&R models to secure a successful business strategy Develop relevant outcomes research projects in the therapeutic area Foster contacts with local industry associations

Regulatory Affairs, Market Access(P&R), Public and Government Relations, Compliance, Clinical Trials, Quality and Pharmacovigilance Leader of Orphan Drugs Subgroup at AIFD